Development of a Tailored Smoking Cessation Program for Individuals With HIV Infection in Washington, D.C.

Sponsor
Colorado State University (Other)
Overall Status
Completed
CT.gov ID
NCT04594109
Collaborator
(none)
25
1
2
7
3.6

Study Details

Study Description

Brief Summary

Morbidity and mortality from smoking-related diseases among people living with HIV (PLWH) in the U.S. surpasses that due to HIV itself. Conventional smoking cessation treatments have not demonstrated strong efficacy among PLWH. We conducted a pilot randomized controlled trial (RCT) to evaluate a tailored smoking cessation intervention based on the minority stress model, hypothesizing that behavioral counseling through this lens would enhance cessation. We compared standard of care counseling (SOC) to a tailored intervention (TI) including one face-to-face counseling session incorporating cognitive behavioral therapy to build resilience, and 30 days of 2-way text messaging.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Tailored behavioral counseling
  • Behavioral: Standard of Care
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
25 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Development of a Tailored Smoking Cessation Program for Individuals With HIV Infection in Washington, D.C.
Actual Study Start Date :
Jun 30, 2017
Actual Primary Completion Date :
Jan 29, 2018
Actual Study Completion Date :
Jan 30, 2018

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Standard of Care

One-time standard of care in-person behavioral counseling lasting approximately one hour, plus a 30-day supply of nicotine replacement therapy consisting of nicotine patches and nicotine gum (dosage according to current smoking intensity according to manufacturers instructions). The standard of care behavioral counseling was adapted from the current U.S. clinical practice guidelines.

Behavioral: Standard of Care
One-time standard of care in-person behavioral counseling lasting approximately one hour, plus a 30-day supply of nicotine replacement therapy consisting of nicotine patches and nicotine gum (dosage according to current smoking intensity according to manufacturers instructions). The standard of care behavioral counseling was adapted from the current U.S. clinical practice guidelines.

Experimental: Tailored Counseling

Participants in the intervention arm were provided a one-time tailored cognitive-behavioral therapy in-person cessation counseling intervention lasting approximately one hour, a 30-day supply of nicotine replacement therapy (consisting of nicotine patches and nicotine gum; dosage according to current smoking intensity according to manufacturers instructions), and a tailored bi-directional text messaging program delivering two messages per day for four weeks. The TI session was adapted from the clinical practice guidelines to include behavioral elements rooted in the minority stress model. The intervention used addressed issues of stress related to HIV stigma, minority status and socioeconomic condition.

Behavioral: Tailored behavioral counseling
Participants in the intervention arm were provided a one-time tailored cognitive-behavioral therapy in-person cessation counseling intervention lasting approximately one hour, a 30-day supply of nicotine replacement therapy (consisting of nicotine patches and nicotine gum; dosage according to current smoking intensity according to manufacturers instructions), and a tailored bi-directional text messaging program delivering two messages per day for four weeks. The TI session was adapted from the clinical practice guidelines to include behavioral elements rooted in the minority stress model. The intervention used addressed issues of stress related to HIV stigma, minority status and socioeconomic condition.

Outcome Measures

Primary Outcome Measures

  1. Smoking Abstinence [30 day follow-up]

    7-day point prevalence plus exhaled breath carbon monoxide < 7 parts per million (ppm)

Secondary Outcome Measures

  1. Cigarettes per day [30 day follow-up]

    Number of cigarettes smoked per day

  2. Exhaled breath carbon monoxide [30 day follow-up]

    Exhaled breath carbon monoxide in parts per million (ppm)

  3. Self-efficacy [30 day follow-up]

    Self-efficacy for smoking abstinence

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ≥18 years of age

  • report being HIV-infected

  • be a resident of the Washington, D.C. area

  • current, daily smokers of tobacco

  • have a confirmed smoking status of 6 parts per million (ppm) or more by using an exhaled carbon monoxide breath monitor

  • agree to participate

  • be willing to set a quit date within 7 days of baseline assessment.

Exclusion Criteria:
  • are currently using smokeless tobacco or electronic cigarettes at least every day

  • are currently using nicotine replacement therapy or other smoking cessation treatment

  • report being HIV-uninfected

  • report having heart disease or high blood pressure not controlled by medication

  • are currently in an alcohol treatment program

  • are pregnant (exclusion items 4-6 are contraindications of nicotine replacement therapy, which will be provided)

  • do not have a primary care provider or HIV care provider to refer to in the event of an adverse reaction to nicotine replacement therapy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Truth Initiative Washington District of Columbia United States 20001

Sponsors and Collaborators

  • Colorado State University

Investigators

  • Principal Investigator: Jessica Elf, PhD MPH, Colorado State University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jessica Elf, Assistant Professor, Colorado State University
ClinicalTrials.gov Identifier:
NCT04594109
Other Study ID Numbers:
  • 00022163
First Posted:
Oct 20, 2020
Last Update Posted:
Oct 20, 2020
Last Verified:
Oct 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 20, 2020